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Severe iron overload and hyporegenerative 
anemia in a case with rhesus hemolytic disease: 
therapeutic approach to rare complications
Rhesus hemolitik hastalıklı bir vakada hiporejeneratif anemi ve aşırı 
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Abstract
A 33 weeks’ gestation, a baby with rhesus hemolytic disease (RHD), who had received intrauterine 
transfusions twice, developed cholestatic hepatic disease and late hyporegenerative anemia. Her 
serum ferritin and bilirubin levels increased to 8842 ng/ml and 17.9 mg/dl, respectively. Liver biopsy 
showed cholestasis and severe iron overload. Treatment with recombinant erythropoietin (rHuEPO) 
decreased the transfusion need, and intravenous deferoxamine resulted in a marked decreased in 
serum ferritin levels and normalization of liver function. In patients who have undergone intrauterine 
transfusions due to RHD, hyperferritinemia and late hyporegenerative anemia should be kept in mind. 
Chelation therapy in cases with symptomatic hyperferritinemia and rHuEPO treatment in cases with 
severe hyporegenerative anemia should be considered. (Turk J Hematol 2010; 27: 204-8)
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Özet
Rhesus hemolitik hastalığı (RHD) tanısıyla izlenen, iki kez intrauterin transfüzyon alan ve 33. gesta-
syonel haftada doğan hastada takipte geç hiporejeneratif anemi ve kolestatik karaciğer hastalığı gelişti. 
Ferritin 8842 ng/mL ve bilirubin 17.9 mg/dL’ye kadar yükseldi. Karaciğer biyopsisinde kolestatik Introduction
The incidence of rhesus hemolytic disease (RHD) 
has significantly declined all over the world with the 
use of prophylactic anti-D immunoglobulin [1]. 
However, in developing countries like Turkey, RHD 
remains a major cause of severe mortality and mor-
bidity since prophylactic anti-D immunoglobulin 
may not be administered appropriately or because 
RHD may develop despite anti-D. Intrauterine trans-
fusions (IUTs) are performed as part of the manage-
ment of neonates who have developed fetal anemia 
due to RHD. Along with technological improve-
ments, IUT can be easily applied to babies with RHD 
and mortality and morbidity ratios may decrease 
distinctly [1,2]. Although there are many detailed 
reports in the literature about anemia and hyperbili-
rubinemia development in RHD, the data about 
complications such as iron overload secondary to 
IUT and hyporegenerative anemia are limited; the 
postnatal management of severely affected infants 
is still challenging. In RHD, the disease itself and IUT 
increase the risk of iron overload and late hypore-
generative anemia [3-8]. The new transfusions, 
which are done postnatally after hyporegenerative 
anemia, usually raise the iron overload and affect 
the prognosis poorly. In this case report, a neonate 
with cholestatic hepatic disease and late hypore-
generative anemia due to RHD is reported to dis-
cuss the therapeutic approach to these complica-
tions in neonates with RHD.
Case Report
A female infant weighing 2335 g was born at 33 
weeks’ gestation to a 22-year-old gravida 3, para 2, 
blood group A Rh-negative woman. The father was 
Rh-positive and the mother had not received any 
anti-D after her deliveries. She had one healthy 
Rh-positive child from her first pregnancy. A second 
baby with hydrops fetalis died intrauterinely. In the 
present pregnancy, indirect Coombs test was found 
positive (anti-D antibody titer 1:256) and the fetus 
received intrauterine 120 ml and 240 ml O 
Rh-negative red cell concentrate transfusions in the 
29th and 31st weeks, respectively. Cord blood hemo-
globins (Hb) were 8.6 g/dl and 6.4 g/dl before the 
IUTs, respectively.
At gestational week 33, the mother presented to 
the obstetric unit of our hospital with uterine con-
tractions. An emergency cesarean section was per-
formed and a baby girl was born with Apgar scores 
of 8 and 10 at 1 and 5 minutes, respectively. On ini-
tial physical examination, the infant was not hydrop-
ic and was transferred to the neonatal intensive 
care unit. Cord blood typing showed O Rh-negative 
blood. Direct Coombs test was negative. A com-
plete blood count at birth revealed a Hb of 10.1 g/dl 
and hematocrit (Hct) of 29.7%. Total bilirubin was 
5.2 mg/dl, with a conjugated fraction of 0.6 mg/dl. A 
transfusion of 15 cc/kg of packed red cell raised the 
Hct to 43%. Bilirubin levels reached a peak of 8.3 
mg/dl by the first day of life and phototherapy was 
given according to standard neonatology protocols.
The patient was discharged home at the fifth day 
of age, with a Hct value of 42%. At four weeks of 
age, she was hospitalized for anemia with a Hct of 
17.6% and reticulocyte count of 0%. Total serum 
bilirubin level was 14.7 mg/dl and conjugated biliru-
bin level was 3.6 mg/dl. Other hematological find-
ings and liver enzymes were normal. On her physi-
cal examination, she was icteric and tachycardic. 
Hepatosplenomegaly was not present. She received 
packed red cell transfusion. Bone marrow examina-
tion showed erythroid hypoplasia. Thirteen days 
later another transfusion was necessary (Hct was 
16.6% and reticulocyte 0.1%). Hyporegenerative 
anemia secondary to RHD was diagnosed, and 
treatment with recombinant human erythropoietin 
(rHuEPO) (250 U/kg by subcutaneous injection, 3 
times a week) was initiated on day 42 of life. After 
initiation of rHuEPO, reticulocytopenia and anemia 
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hepatit ve aşırı demir birikimi saptandı. Rekombinan erythropoietin (rHuEPO) ile transfüzyon ihtiyacı 
azaldı. İntravenöz desferoxamine ile karaciğer fonksiyon testleri ve serum ferritin değerleri normale 
döndü. Sonuç olarak, RHD nedeniyle intrauterin transfüzyon tedavisi yapılan hastalarda hiporejen-
eratif anemi ve hiperferritinemi gelişebilir. Semptomatik hiperferritinemi durumunda şelasyon teda-
visi, hiporejeneratif anemi durumunda da rHuEPO tedavisi göz önünde bulundurulmalıdır. 
(Turk J Hematol 2010; 27: 204-8)
Anahtar kelimeler: Rh hemolitik hastalığı, geç hiporejeneratif anemi, transfüzyona ikincil karaciğer 
demir birikimi, şelasyon tedavisi
Geliş tarihi:10 Mayıs 2009    Kabul tarihi: 10 Aralık 2009continued for two weeks and she had to be trans-
fused again (Figure 1). By the end of the third week, 
reticulocyte count increased and Hb level stabi-
lized. rHuEPO was discontinued after six weeks of 
treatment; Hb was 12.6 g/dl and reticulocyte count 
was 13%. Paralleling the increase in conjugated bili-
rubin from hemolysis, the conjugated bilirubin frac-
tion rose to 3.6 mg/dl on the postnatal 30th day. 
From the time of her rehospitalization, liver trans-
aminases increased progressively and reached 
peak aspartate aminotransferase (AST) of 105 U/L 
(normal ranges, 1 to 32 U/L) and alanine amino-
transferase (ALT) of 142 U/L (normal ranges, 1 to 31 
U/L) on the 40th day. The tests for final and differen-
tial diagnosis of conjugated bilirubinemia were 
done in order to determine the underlying patholo-
gy. TANDEM mass spectrometry, urine-blood amino 
acid chromatography, sweat test, and α1-antitrypsin 
test were normal. Serological test results for TORCH, 
hepatitis A, B, and C, Epstein-Barr virus, and parvo-
virus were negative. The ferritin level was found to 
be 4620 ng/ml on day 40. A liver biopsy performed 
at 7 weeks of age showed histological features con-
sistent with iron overload with hepatocytes with 
hemosiderin pigment, fibrosis of the portal tracts, 
and canalicular cholestasis (Figure 2). Liver iron 
concentration was 6320 ug Fe/g dry weight (normal 
ranges 200 to 2400 ug Fe/g dry weight). After biopsy, 
she had to be transfused and both conjugated and 
unconjugated bilirubin levels increased (at the 60th 
day, unconjugated bilirubin: 17.9 mg/dl and conju-
gated bilirubin: 12.4 mg/dl). Ferritin levels also 
increased to 8842 ng/ml. The oral mucosa biopsy 
that was performed for the neonatal hemochroma-
tosis differential diagnosis was normal. Deferoxamine 
(30 mg/kg/daily intravenous, 5 times per week) was 
started with these clinical and laboratory features. 
No side effect was noted during chelation therapy. 
On follow up, bilirubin levels decreased after the 
first week of iron chelation and normalized at the 
10th week of iron chelation therapy (Figure 3). The 
serum ferritin level decreased to 684 ng/ml and che-
lation therapy was stopped (Figure 4). The infant 
was discharged from the hospital in good clinical 
condition. When she was six months old, physical 
examination findings and complete blood cell count 
were in normal ranges and the reticulocyte count 
was 3.2%. Her blood group was A Rh-positive and 
direct Coombs test was negative. Liver function 
tests showed a significant improvement with total 
bilirubin 0.4 mg/dl, conjugated bilirubin 0.2 mg/dl, 
ALT 64 U/L, AST 45 U/L, and serum ferritin level 249 
ng/ml. Liver biopsy was not repeated.
Oral informed of consent was ontained from the 
patient.
Discussion
Intrauterine transfusions (IUTs) have markedly 
decreased the risk of hydrops fetalis and stillbirth of 
infants with RHD, but it can be a rare cause of com-
plications like hyporegenerative anemia and symp-
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Figure 1. Need for erythrocyte transfusion was decreased with 
recombinant erythropoietin treatment
Figure 2A and 2B. Histological appearance of the liver biopsy. Note 
the brownish pigment in the hepatocytes in Figure A (H&E stain-
ing, x100) consistent with bluish-stained iron in Figure B (Prussia 
staining, x100)
Figure 3. The bilirubin level was normalized with chelation therapytomatic iron overload [1]. Hyporegenerative anemia 
is characterized by depressed erythropoiesis with 
reduction in circulating reticulocyte count and low 
or undetectable numbers of erythrocytes containing 
fetal hemoglobin. It is seen between 2 to 6 weeks 
after birth and the pathogenesis is still unclear. The 
possible explanations of anemia are intramedullary 
destruction of normoblasts with Rh antibodies and 
low erythropoietin levels due to suppression of the 
bone marrow by IUT [1,6,9]. These patients require 
erythrocyte transfusions in the postnatal period, and 
the use of rHuEPO may reduce the need for postna-
tal transfusions [10-13]. Even though rHuEPO 
administration is highly effective in many patients, 
treatment of hyporegenerative anemia with rHuEPO 
may be ineffective when anti-D titers are high [14]. 
Anemia of prematurity (our patient was born at 33 
weeks’ gestation) is a multifactorial disease associ-
ated with relatively low plasma erythropoietin levels 
and insufficient erythropoiesis. Other complicating 
variables including small circulating blood volume, 
iatrogenic blood loss, hemorrhage, hemolysis, and 
shortened red blood cell survival also contribute to 
anemia in premature newborns. It occurs in 1-3 
months after birth, and is associated with hemoglo-
bin levels below 7-10 g/dl. Traditionally, anemia of 
prematurity has been treated with frequent packed 
erythrocyte transfusions [15]. We evaluated our 
patient as late hyporegenerative anemia because of 
reticulocytopenia and significant erythroid hypopla-
sia. History of IUT secondary to RHD is an important 
point for the differential diagnosis of anemia of pre-
maturity. Our patient showed good response to 
rHuEPO and required no further transfusions after 
the second week of therapy.
Iron metabolism is dynamic in the fetal and neo-
natal periods. In the intrauterine period, iron is taken 
up as transferrin from maternal plasma by the pla-
cental trophoblasts. Ferritin levels rise during preg-
nancy and iron load is much more than adults in the 
neonatal period. These iron depots progressively 
decrease to normal limits in the first year of life [16-
18]. Iron load decreases due to decreased placental 
iron transport in patients with intrauterine growth 
retardation, preeclampsia, hypertension, and diabe-
tes mellitus, whereas it increases with delayed 
clamping of the umbilical cord, twin to twin transfu-
sion and intrauterine hemolysis with RHD [3,5,16,17]. 
Iron deposits can be seen during non-alcoholic 
liver disease and chronic hepatitis C infection. 
Insulin resistance and the influence of iron metabo-
lism can lead to iron deposits in these patients. In 
the case of insulin resistance, increased insulin and 
proinflammatory cytokines and decreased hemo-
jevulin and ferroportin-1 from hepatocytes are attrib-
uted to iron deposits due to decreased iron excre-
tion from hepatocytes. Furthermore, in chronic 
hepatitis C infection, decreased hepcidin also leads 
to iron deposits as well as insulin resistance [18,19]. 
In our patient, overload iron deposits could have 
caused the liver damage, or on the other hand, liver 
damage could have led to iron deposits via its effect 
on hepcidin, hemojevulin and ferroportin-1 metab-
olism. Furthermore, intrauterine hypoxia due to 
anemia caused by Rh immunization can contribute 
to increased serum ferritin levels and liver function 
tests. Hypoxia-induced inflammation can cause the 
increase in hepcidin and ferritin synthesis. Hepcidin 
is a peptide hormone that inhibits intestinal iron 
absorption, iron recycling by macrophages, and iron 
mobilization from hepatic stores, and synthesis of 
hepcidin is increased by iron loading [1,20,21].
The clinical course of RHD patients with excess 
iron load is variable; while most cases have no clini-
cal findings, chelation therapy can be necessary in 
some cases with severe organ damage [22-25]. 
Ferritin and hepatic iron content are extremely vari-
able in neonates such that there are no definite crite-
ria for chelation therapy. Chelation therapy is recom-
mended for patients with clinical and histopathologic 
evidence of iron overload, as in our patient [23,25,26]. 
Our patient had hyperferritinemia, cholestatic liver 
disease, and iron overload at liver biopsy. Chelation 
therapy resulted in rapid reduction in ferritin levels. 
In the literature, chelation therapy was required for 
6-12 weeks [23,24]. In our case, chelation therapy 
was given for 10 weeks.
In conclusion, in patients who have undergone 
IUT due to RHD, hyperferritinemia and late hypore-
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Figure 4. Ferritin values were successfully decreased with chela-
tion therapygenerative anemia should be kept in mind. Chelation 
therapy in cases with symptomatic hyperferri-
tinemia and rHuEPO treatment in cases with severe 
hyporegenerative anemia should be considered.
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